Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2011

View Archived Issues

HspB8 blocks autophagy in breast cancer cells, conferring resistance to tamoxifen

AV-7909 improves survival of ciprofloxacin-treated guinea pigs exposed to B. anthracis

AB-103 protects mice from SEB- and LPS-induced lethal shock

Bakuchiol cream is efficacious against acne in open-label trial

Etanercept demonstrates little activity to date in phase II trial in discoid lupus erythematosus

BAY-86-4367 effectively targets prostate tumors in preclinical study

Gentium completes defibrotide studies in veno-occlusive disease and prepares regulatory filings

GSK to launch new alli chewable tablet as weight loss aid

Phase IIb trial to compare delafloxacin to linezolid and vancomycin in ABSSSI

EMA grants orphan drug status to GT-038 in retinitis pigmentosa

Treatment begins in phase I elesclomol trial in acute myeloid leukemia

CytRx reports preclinical data on bafetinib in cancer-related bone loss

Elan and Boehringer Ingelheim to codevelop antibody-based therapeutics

R-Tech Ueno begins phase I trial to test RL-023's safety as therapy for eyelash hypotrichosis

Clinuvel completes phase II Scenesse trial in erythropoietic protoporphyria

Biovail Labs acquires Canadian license for Aczone from Allergen

Pervasis Therapeutics' Vascugel receives FDA fast track status

AMAG receives NON from Health Canada regarding Feraheme submission

Johnson & Johnson reports highlights fourth quarter 2010

Circassia acquires worldwide rights to psoriasis and atopic dermatitis treatment PAP-1

A.P. Pharma provides company update

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...